🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 21 of 151

  1. BAY1002670

    Bayer HealthCare AG

    Leiomyoma

    phase 2 small molecule completed

    1 trial

  2. BAY2757556 (Larotrectinib, Vitrakvi)

    Bayer HealthCare AG

    Solid Tumors Harboring NTRK Fusion

    phase 2 small molecule completed

    1 trial

  3. BB-301: Dose escalation phase 1b cohort 1

    Benitec Biopharma

    Oculopharyngeal Muscular Dystrophy

    phase 2 gene therapy active

    1 trial

  4. BB-401

    Benitec Biopharma

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  5. BBI608

    Sumitomo Pharma (Suzhou) Co.,

    Malignant Pleural Mesothelioma

    phase 2 small molecule completed

    1 trial

  6. BBP-398, CETUXIMAB, ADAGRASIB

    Bristol-Myers Squibb Australia Pty Ltd

    Oncology, NSCLC and CRC

    phase 2 small molecule active

    1 trial

  7. BC1 cell line

    BriaCell Therapeutics

    Breast Cancer

    phase 2 mab active

    1 trial

  8. BCG (50mg/instillation) + N-803 (400 μg/instillation)

    Immunitybio Ireland Limited

    Non-muscle Invasive Bladder Cancer

    phase 2 mab active

    1 trial

  9. BCG-MEDAC, poudre et solvant pour suspension intravésicale, PD1IL2v iMAb

    Hoffmann-La Roche

    BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)

    phase 2 small molecule active

    1 trial

  10. BCMA CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma, Plasma Cell Leukemia

    phase 2 mab active

    1 trial

  11. BCMA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Multiple Myeloma

    phase 2 mab active

    2 trials

  12. BCMA CART

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm Definitions

    phase 2 small molecule active

    1 trial

  13. BCMA targeted prime CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Multiple Myeloma

    phase 2 mab active

    1 trial

  14. BCMA/CD3 bispecific antibody (CM336)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Solitary Bone Plasmacytoma

    phase 2 small molecule active

    1 trial

  15. BCT197

    Mereo BioPharma Group plc

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial

  16. BCT197

    Mereo BioPharma Group plc

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  17. BCT197 Part A

    Mereo BioPharma Group plc

    Acute Kidney Injury

    phase 2 small molecule terminated

    1 trial

  18. BCX-1777

    Biocryst

    Leukemia, Lymphocytic

    phase 2 small molecule completed

    1 trial

  19. BCX17725

    Lacuna Pharma Pty Ltd

    Netherton Syndrome

    phase 2 small molecule active

    1 trial

  20. BCX7353

    Biocryst

    Hereditary Angioedema (HAE)

    phase 2 small molecule completed

    2 trials

  21. BCX9930

    Biocryst

    Complement 3 Glomerulopathy

    phase 2 small molecule terminated

    1 trial

  22. BCX9930

    Biocryst

    Paroxysmal Nocturnal Hemoglobinuria

    phase 2 small molecule terminated

    3 trials

  23. BDB001

    Eikon Therapeutics

    Tumor, Solid

    phase 2 small molecule completed

    1 trial

  24. BDC-1001

    Bolt Biotherapeutics

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  25. BDC-1001

    Bolt Biotherapeutics

    HER2-positive Solid Tumors

    phase 2 small molecule terminated

    1 trial

  26. BDC-1001, PERTUZUMAB

    Bolt Biotherapeutics

    HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE METASTATIC BREAST CANCER

    phase 2 small molecule active

    1 trial

  27. BDC-4182

    Bolt Biotherapeutics

    Gastric Cancer Adenocarcinoma Metastatic

    phase 2 small molecule active

    1 trial

  28. BEAM-101

    Beam Therapeutics

    Sickle Cell Disease

    phase 2 mab active

    1 trial

  29. BEAM-201

    Beam Therapeutics

    Lymphoblastic Lymphoma

    phase 2 mab active

    1 trial

  30. BEAM-301: Single dose of BEAM-301 administered by IV

    Beam Therapeutics

    Glycogen Storage Disease Type Ia

    phase 2 small molecule active

    1 trial

  31. BEAM-302

    Beam Therapeutics

    Alpha 1-Antitrypsin Deficiency

    phase 2 small molecule active

    1 trial

  32. BEAM-302

    Beam Therapeutics

    Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease

    phase 2 small molecule active

    1 trial

  33. BEKINDA

    RedHill Biopharma

    Irritable Bowel Syndrome With Diarrhea

    phase 2 small molecule completed

    1 trial

  34. BENDAFOLIN 10 mg/ml Injektionslösung, Gemcitabin HEXAL® 40 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Benda-5 FU 50 mg/ml Injektionslösung, Onivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion, Irinotecan Bendalis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, AZD0901

    AstraZeneca AB

    Gastric Cancer, Gastroesophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  35. BENDAMUSTINE , CYTARABINE , VENETOCLAX , RITUXIMAB

    Fondazione Telethon ETS

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  36. BET-Inhibitor, Jakavi 5 mg tablets, Jakavi 10 mg tablets, Jakavi 15 mg tablets, FEDRATINIB

    Bristol-Myers Squibb Australia Pty Ltd

    DIPSS-Intermediate or High Risk Myelofibrosis

    phase 2 small molecule active

    1 trial

  37. BEVACIZUMAB

    Pari Pharma GmbH

    Adult patients with persistent dyspnea more than 3 months after acute COVID-19 infection.

    phase 2 small molecule active

    1 trial

  38. BEVACIZUMAB, ATEZOLIZUMAB

    Pari Pharma GmbH

    liver transplanted patients with advanced hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  39. BEVACIZUMAB, DC-VACCINE_IRSTIRCCS, Lonsurf 20 mg/8.19 mg film-coated tablets, VEGZELMA 25 mg/mL concentrate for solution for infusion, VEGZELMA 25 mg/mL concentrate for solution for infusion, Lonsurf 15 mg/6.14 mg film-coated tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion, BEVACIZUMAB

    Istituto Gentili S.r.l.

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  40. BEVACIZUMAB, IRINOTECAN, FOLINIC ACID, Telisotuzumab adizutecan, FLUOROURACIL

    AbbVie Deutschland GmbH & Co. KG

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  41. BEVACIZUMAB, PEMBROLIZUMAB, VINORELBINE, GEMCITABINE, NIVOLUMAB, PEMETREXED, PACLITAXEL, CARBOPLATIN

    CERO THERAPEUTICS HOLDINGS, INC.

    Non Small Cell Lung Cancer, Interstitial Lung Disease

    phase 2 small molecule active

    1 trial

  42. BFB759, Placebo

    Blue Earth Diagnostics Ireland Ltd

    Atopic dermatitis

    phase 2 small molecule active

    1 trial

  43. BGB-10188

    BEONE MEDICINES AUS PTY LTD

    Chronic Lymphocytic Leukemia

    phase 2 small molecule completed

    1 trial

  44. BGB-11417

    BEONE MEDICINES AUS PTY LTD

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  45. BGB-11417

    BEONE MEDICINES AUS PTY LTD

    Leukemia

    phase 2 small molecule active

    1 trial

  46. BGB-11417, POSACONAZOLE, Azacitidine betapharm 25 mg/mL powder for suspension for injection, BGB-11417, BGB-11417, AZACITIDINE

    BEONE MEDICINES AUS PTY LTD

    Myeloid malignancies (acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN.

    phase 2 small molecule active

    1 trial

  47. BGB-11417, Zanubrutinib, BGB-11417, BGB-11417, BGB-11417

    BEONE MEDICINES AUS PTY LTD

    Previously Untreated Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  48. BGB-11417, Zanubrutinib, BGB-11417, BGB-11417, BGB-11417

    BEONE MEDICINES AUS PTY LTD

    previously untreated chronic lymphocytic leukemia (CLL)

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.